SEC Form 4 · accession 0001179110-18-010467
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradford J Shafer
Officer — EVP, Gen. Counsel, Secretary
Period of report
Aug 7, 2018
Accepted (ET)
Aug 9, 2018 · 7:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 7, 2018 | S | 1,818 | $28.9916 | D | 127,606 | D | |
| Ordinary SharesF2 | Aug 7, 2018 | S | 4,127 | $28.0315 | D | 123,479 | D | |
| Ordinary SharesF3 | Aug 8, 2018 | S | 25,355 | $27.8518 | D | 98,124 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices from $28.60 to $29.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices from $28.015 to $28.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices from $27.63 to $28.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.